Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.
James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).
Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
